^
Association details:
| Biomarker: | ER mutation |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Published date:
09/01/2016
Excerpt:
Fulvestrant plus palbociclib improved PFS compared with fulvestrant plus placebo in both ESR1 mutant (HR, 0.43; 95% CI, 0.25 to 0.74; P = .002) and ESR1 wild-type patients (HR, 0.49; 95% CI, 0.35 to 0.70; P < .001).
Secondary therapy:
fulvestrant
DOI:
10.1200/JCO.2016.67.3061
Trial ID:
Source:
Title:
A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.
Excerpt:
...Provision of blood sample to test ESR1 mutation status and for other biomarker assessment....
Trial ID:
Source:
Title:
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
Excerpt:
...- Hematological safety of patients with bone metastases will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.- Progression-Free Survival (PFS) will be measured from the time of randomization (following rising ESR1 mutation detection) to the time of tumor progression (as assessed by the investigator per RECIST v1.1) or death (whichever comes first) – in randomized patients....
Trial ID:
